ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
131.065,44
-1,55%
S&P 500
5.702,55
-0,19%
US Dollar vs BRL
5,5151
0,00%
Bitcoin
62.840,01
-0,85%
Brent Oil
74,135
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Alnylam Pharmaceuticals Inc (ALNY)

  7. Alnylam Pharmaceuticals Inc (ALNY) Notícias

ALNY

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALNY
DataHoraFonteTítuloCódigoCompanhia
30/08/202417:03Business WireAlnylam présente les résultats détaillés de l'étude de phase 3 HELIOS-B positive de Vutrisiran▼ chez les patients atteints d'amylose ATTR avec cardiomyopathie au congrès de la Société européenne de cardiologieNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/08/202414:10Business WireAlnylam präsentiert detaillierte Ergebnisse der positiven HELIOS-B-Phase-3-Studie mit Vutrisiran▼ bei Patienten mit ATTR-Amyloidose mit Kardiomyopathie auf dem Kongress der Europäischen Gesellschaft für KardiologieNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/08/202407:00Business WireAlnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology CongressNASDAQ:ALNYAlnylam Pharmaceuticals Inc
28/08/202417:00Business WireAlnylam to Webcast Presentations at Upcoming September Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
22/08/202421:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/08/202418:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/08/202423:08Business WireEuropäischer Kardiologenkongress 2024: Alnylam legt detaillierte Ergebnisse der Phase-3-Studie HELIOS-B zu Vutrisiran▼ bei ATTR-Amyloidose mit Kardiomyopathie vorNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/08/202420:04Business WireAlnylam présentera des résultats détaillés de l'étude HELIOS-B de phase 3 pour le vutrisiran▼ chez les patients atteints d'amylose ATTR avec cardiomyopathie lors du congrès 2024 de la Société européenne de cardiologieNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/08/202409:00Business WireAlnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024NASDAQ:ALNYAlnylam Pharmaceuticals Inc
01/08/202409:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
01/08/202409:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
01/08/202409:00Business WireAlnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/07/202409:00Business WireAlnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
24/06/202408:00Business WireAlnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy PopulationsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/05/202409:00Business WireAlnylam Issues 2023 Corporate Responsibility ReportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/05/202409:00Business WireAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/04/202408:00PR Newswire (Canada)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/04/202409:00Business WireAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/04/202409:00Business WireAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled HypertensionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/03/202409:00Business WireAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/03/202408:30Business WireAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive DiseaseNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202408:50Business WireAlnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegenNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202419:39Business WireAlnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standardsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202409:30Business WireAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
27/02/202410:30Business WireAlnylam to Webcast Presentations at Upcoming March Investor ConferencesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
15/02/202418:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
15/02/202410:00Business WireAlnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
09/02/202420:14Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALNYAlnylam Pharmaceuticals Inc
29/01/202410:00Business WireAlnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
09/01/202410:05Business WireAlnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s AssociationNASDAQ:ALNYAlnylam Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALNY

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AGXY3
Agrogalaxy Participacoes ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados